Inflammatory faCtors AfteR acUte Ischemic Stroke

Ischemic Stroke Clinical Trial

— ICARUS  

Official title:

Inflammatory faCtors AfteR acUte Ischemic Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04412187
• Other study ID #: 19-428
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2024
• Source: Ludwig-Maximilians - University of Munich
• Contact: Martin Dichgans, Prof.
• Phone: +49 4400
• Email: martin.dichgans[@]med.uni-muenchen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes.

ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct.

In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

Description:

The neuroinflammatory response after ischemic brain injury has been identified as a pathomechanism in ischemic stroke. Stroke induces an activation of microglia in the brain, which lasts over months. However, the characteristics and mechanisms of this microglia activation are insufficiently defined.

Our study hypotheses are (i) that a subpopulation of patients with acute stroke develop prominent microglial activation, and (ii) that patients with extensive microglial activation are more likely to experience poor outcome.

Against this background, the investigators set up the "Inflammatory faCtors AfteR acUte ischemic Stroke (ICARUS)" study as an interventional single-centre hospital-based cohort study. N=36 patients with a cortical (N=18) or strictly subcortical (N=18) acute ischemic stroke will be recruited through the local stroke unit (Department of Neurology, LMU Munich). Study participation involves serial TSPO-PET imaging along with serial MR imaging, immune cell profiling in blood, and both clinical and laboratory assessments. Follow-up assessments at 3 weeks, 3 months, 6 months and 12 months will be conducted at the Institute for Stroke and Dementia Research (ISD) and at the Department of Nuclear medicine, both LMU Munich.

In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer. These patients will receive dynamic PET in addition to the ASL sequences.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Age = 50 years

• Acute ischemic stroke (time frame: <72 hours) as defined by an acute focal neurological deficit in combination with a corresponding infarct as documented by a diffusion weighted imaging (DWI)-positive lesion on magnetic resonance imaging (MRI); presence of an infarct involving the cortex or a strictly subcortical infarct

• Written informed consent prior to study participation

• Willingness to participate in study assessments including follow-up

Exclusion Criteria:

• Unwillingness or inability to give written consent

• Prior history of stroke, multiple infarcts, infratentorial infarcts affecting the brain stem or cerebellum

• Known diseases of the CNS other than stroke

• Immunomodulatory therapies within the last 3 months prior stroke

• Chronic inflammatory disease

• Infectious diseases within the last 7 days prior stroke

• Conditions interfering with follow-up such as end-stage malignancy

• Contraindications for MRI or PET (pacemaker, aneurysm clip, cochlear implant etc.)

• Radiation exposure of > 10mSv per year

• Pregnant or breastfeeding women

• Participation in a clinical trial

Related Conditions & MeSH terms

• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Diagnostic Test:
• [18F]-GE-180 PET
serial [18F]-GE-180 PET imaging to assess microglia activation
• 3T MRI
serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
• immune cell profiling in blood
Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.

Locations

Country	Name	City	State
Germany	Department of Nuclear Medicine	Munich
Germany	Insitute for Stroke and Dementia Research	Munich

Sponsors (3)

Lead Sponsor	Collaborator
Martin Dichgans	Universitätsklinikum Hamburg-Eppendorf, University Hospital Muenster

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	microglia activation in patients with acute stroke	Microglia activation will be assessed using TSPO PET imgaing.	within 10 days after acute ischemic stroke
Primary	microglia activation in patients with acute stroke	Microglia activation will be assessed using TSPO PET imgaing.	3 months after acute ischemic stroke
Primary	functional outcome in patients after acute ischemic stroke	Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.	3 weeks after acute ischemic stroke
Primary	functional outcome in patients after acute ischemic stroke	Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.	3 months after acute ischemic stroke
Primary	functional outcome in patients after acute ischemic stroke	Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.	6 months after acute ischemic stroke
Primary	functional outcome in patients after acute ischemic stroke	Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.	12 months after acute ischemic stroke
Primary	cognitive outcome in patients after acute ischemic stroke	Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.	3 weeks after acute ischemic stroke
Primary	cognitive outcome in patients after acute ischemic stroke	Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.	3 months after acute ischemic stroke
Primary	cognitive outcome in patients after acute ischemic stroke	Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.	6 months after acute ischemic stroke
Primary	cognitive outcome in patients after acute ischemic stroke	Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.	12 months after acute ischemic stroke
Secondary	inflammatory markers in blood	Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.	3 weeks after acute ischemic stroke
Secondary	inflammatory markers in blood	Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.	3 months after acute ischemic stroke
Secondary	Duplex ultrasound	Duplex ultrasound will be performed to assess potential progress of atherosclerosis related to inflammatory markers	6 months after acute ischemic stroke
Secondary	3T MR imaging	3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.	3 months after acute ischemic stroke
Secondary	3T MR imaging	3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.	12 months after acute ischemic stroke